Our mission: Accelerating the Development of Drugs to Prevent and Treat Alzheimer's Disease

OUR STRATEGY
Funding diverse, innovative ideas that reflect the latest science, not well-worn paths.

DIAGNOSTICS ACCELERATOR
The path to approved Alzheimer’s treatments starts with a better way to diagnose patients. Bill Gates and ADDF co-founder Leonard Lauder partnered to create the Diagnostics Accelerator to advance bold new ideas for easier and more accurate diagnosis of Alzheimer’s disease and related dementias. Learn more at Alzdiscover.org/accelerator.

PREVENTION
Prevention is an important part of our mission. At CognitiveVitality.org, we empower you to make smart, science-backed choices about brain health. Our neuroscientists conduct in-depth evaluations of potential treatments, ranging from FDA-approved drugs to natural products and supplements, and then rate them by levels of effectiveness and safety.

RESOURCES
The ADDF’s commitment to accelerating Alzheimer’s drug discovery is comprehensive. We organize conferences across the U.S. and overseas to bring the field together to share findings and expertise, and we created ADDF ACCESS, a website to help scientists get the services they need as the scope of their research increases.

Founded in 1998 by Leonard A. Lauder and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is the only philanthropy solely focused on accelerating the development of drugs to prevent and treat Alzheimer’s disease. Its venture philanthropy approach and scientific expertise allows the ADDF to support the most promising ideas around the world.

Our team of expert neuroscientists find and fund drug discovery projects that have the best chance of preventing or treating Alzheimer’s and related dementias. Drug discovery is a chronically underfunded area, so our investments mean good ideas get explored. And every idea is a chance at a cure.
Our Impact

The ADDF provided initial funding for the Amyvid™ PET scan, the FIRST FDA-APPROVED DIAGNOSTIC TEST to identify Alzheimer’s disease in living patients before the onset of symptoms, revolutionizing clinical trials for Alzheimer’s.

MORE THAN 20% of all treatments now in clinical trials for Alzheimer’s have been supported by the ADDF, and they encompass a diverse range of targets. Every single one represents hope for the tens of millions of people across the globe affected by this disease.

TOGETHER, WE WILL CONQUER ALZHEIMER’S

All fundraising and management expenses are underwritten by our founders, so your entire donation funds the most innovative drug research around the world.